Biotech Values

[DewDiligence]

>DNDN said at the advisory panel meeting that they didn't have a lot of cash to provide Provenge on a CU basis to everyone who might want it and wait several years for the results of the 9902b trial before getting approval.<

Let me reiterate the points in my prior post (#msg-18765980):

1. If Provenge is as promising as some people think, surely there are ample sources of capital to complete the clinical program.

2. Finance is not the FDA’s bailiwick. (Are you seriously suggesting that the FDA should approve Provenge merely to facilitate funding of the 9902b trial?)

Regards, Dew

p.s. I do not understand why you brought IMCL into the discussion; it’s not relevant.